ADCT

ADC Therapeutics SA

3.18 USD
+0.02 (+0.63%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

ADC Therapeutics SA stock is down -23% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
23 Apr 14:09 17 May, 2024 5.00 CALL 999 218

About ADC Therapeutics SA

ADC Therapeutics SA develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial.